The Risk of Dermatological Toxicities of Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma Patients: A Systematic Review and Meta-Analysis

    December 2018 in “ Cutaneous and Ocular Toxicology ”
    Peng Chen, Fucaho Chen, Benhong Zhou
    Studysummary This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Vemurafenib-Induced Pityriasis Amiantacea: A Case Report Cutaneous and ocular toxicology · 2015